nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.07.2012 | Original Article

Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas

verfasst von: Alexander Heinzel, Stephanie Stock, Karl-Josef Langen, Dirk Müller

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Several diagnostic trials have indicated that the combined use of ¹⁸F-fluoroethyl-l-tyrosine (FET) PET and MRI may be superior to MRI alone in selecting the biopsy site for the diagnosis of gliomas. We estimated the cost-effectiveness of the use of amino acid PET compared to MRI alone from the perspective of the German statutory health insurance.

Methods

To evaluate the incremental cost-effectiveness of the use of amino acid PET, a decision tree model was built. The effectiveness of FET PET was determined by the probability of a correct diagnosis. Costs were estimated for a baseline scenario and for a more expensive scenario in which disease severity was considered. The robustness of the results was tested using deterministic and probabilistic sensitivity analyses.

Results

The combined use of PET and MRI resulted in an increase of 18.5% in the likelihood of a correct diagnosis. The incremental cost-effectiveness ratio for one additional correct diagnosis using FET PET was €6,405 for the baseline scenario and €9,114 for the scenario based on higher disease severity. The probabilistic sensitivity analysis confirmed the robustness of the results.

Conclusion

The model indicates that the use of amino acid PET may be cost-effective in patients with glioma. As a result of several limitations in the data used for the model, further studies are needed to confirm the results.

Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, et al. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med. 2007;48(4):519–27.PubMedCrossRef

Deb P, Sharma MC, Mahapatra AK, Agarwal D, Sarkar C. Glioblastoma multiforme with long term survival. Neurol India. 2005;53(3):329–32.PubMedCrossRef

Walid MS, Smisson III HF, Robinson Jr JS. Long-term survival after glioblastoma multiforme. South Med J. 2008;101(9):971–2.PubMedCrossRef

Scoccianti S, Magrini SM, Ricardi U, Detti B, Buglione M, Sotti G, et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery. 2010;67(2):446–58.PubMedCrossRef

Grant R. Overview: brain tumour diagnosis and management/Royal College of Physicians guidelines. J Neurol Neurosurg Psychiatry. 2004;75 Suppl 2:ii18–23.PubMedCrossRef

Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R. Gliomas in adults. Dtsch Arztebl Int. 2010;107(45):799–808.PubMed

Stupp R, Roila F. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19 Suppl 2:ii83–5.PubMedCrossRef

Kaufman HH, Catalano Jr LW. Diagnostic brain biopsy: a series of 50 cases and a review. Neurosurgery. 1979;4(2):129–36.PubMedCrossRef

Sawyer J, Ellner J, Ransohoff DF. To biopsy or not to biopsy in suspected herpes simplex encephalitis: a quantitative analysis. Med Decis Mak. 1988;8(2):95–101.CrossRef

10.

DeAngelis LM. Brain tumors. N Engl J Med. 2001;344(2):114–23.PubMedCrossRef

11.

Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48(9):1468–81.PubMedCrossRef

12.

Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, et al. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33(3):287–94.PubMedCrossRef

13.

Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med. 2004;45(8):1293–8.PubMed

14.

Langen KJ, Floeth FW, Stoffels G, Hamacher K, Coenen HH, Pauleit D. Improved diagnostics of cerebral gliomas using FET PET. Z Med Phys. 2007;17(4):237–41.PubMedCrossRef

15.

Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med. 1997;38(9):1459–62.PubMed

16.

Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004;10(21):7163–70.PubMedCrossRef

17.

Miwa K, Shinoda J, Yano H, Okumura A, Iwama T, Nakashima T, et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry. 2004;75(10):1457–62.PubMedCrossRef

18.

Muragaki Y, Chernov M, Maruyama T, Ochiai T, Taira T, Kubo O, et al. Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate? Minim Invasive Neurosurg. 2008;51(5):275–9.PubMedCrossRef

19.

Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Müller HW, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128(Pt 3):678–87.PubMedCrossRef

20.

Pirotte B, Goldman S, Bidaut LM, Luxen A, Stanus E, Brucher JM, et al. Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy. Acta Neurochir (Wien). 1995;134(1–2):79–82.CrossRef

21.

Langen KJ, Bartenstein P, Boecker H, Brust P, Coenen HH, Drzezga A, et al. German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids. Nuklearmedizin. 2011;50(4):167–73.PubMedCrossRef

22.

Vander BT, Asenbaum S, Bartenstein P, Halldin C, Kapucu O, Van Laere K, et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging. 2006;33(11):1374–80.CrossRef

23.

Heinzel A, Stock S, Langen KJ, Müller D. Cost-effectiveness analysis of amino acid PET guided surgery for supratentorial high-grade gliomas. J Nucl Med. 2011; in Press.

24.

Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Mak. 1985;5(2):157–77.CrossRef

25.

Meltzer MI, Dennis DT, Orloski KA. The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis. 1999;5(3):321–8.PubMedCrossRef

26.

Burgos JL, Gaebler JA, Strathdee SA, Lozada R, Staines H, Patterson TL. Cost-effectiveness of an intervention to reduce HIV/STI incidence and promote condom use among female sex workers in the Mexico-US border region. PLoS One. 2010;5(6):e11413.PubMedCrossRef

27.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedCrossRef

28.

Uyl-de Groot CA, Stupp R, van der Bent M. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Expert Rev Pharmacoecon Outcomes Res. 2009;9(3):235–41.PubMedCrossRef

29.

Plotkin M, Blechschmidt C, Auf G, Nyuyki F, Geworski L, Denecke T, et al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur Radiol. 2010;20(10):2496–502.PubMedCrossRef

30.

Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol. 1998;49(4):436–40.PubMedCrossRef

31.

Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133(6):455–63.PubMed

32.

Miller FG, Brody H. What makes placebo-controlled trials unethical? Am J Bioeth. 2002;2(2):3–9.PubMedCrossRef

Titel: Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas
verfasst von: Alexander Heinzel
Stephanie Stock
Karl-Josef Langen
Dirk Müller
Publikationsdatum: 01.07.2012
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-012-2093-0

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2012

Even in times of crisis the distribution of knowledge is …

Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease

Lymphoscintigraphy and SPECT/CT in multicentric and multifocal breast cancer: does each tumour have a separate drainage pattern?

Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

PET/MR imaging of bone lesions – implications for PET quantification from imperfect attenuation correction

Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor